Defective T-cell response to COVID-19 vaccination in acute myeloid leukaemia and myelodysplastic syndromes.

Autor: Loke J; Centre for Clinical Haematology, Queen Elizabeth Hospital, Birmingham, UK.; CRUK Clinical Trials Unit, University of Birmingham, Birmingham, UK.; Dana Farber Cancer Institute, Boston, Massachusetts, USA., Upasani V; University College London, London, UK., Gaskell C; CRUK Clinical Trials Unit, University of Birmingham, Birmingham, UK., Fox S; CRUK Clinical Trials Unit, University of Birmingham, Birmingham, UK., Fletcher R; CRUK Clinical Trials Unit, University of Birmingham, Birmingham, UK., Thomas C; CRUK Clinical Trials Unit, University of Birmingham, Birmingham, UK., Hopkins L; CRUK Clinical Trials Unit, University of Birmingham, Birmingham, UK., Kumari A; CRUK Clinical Trials Unit, University of Birmingham, Birmingham, UK., Tang T; CRUK Clinical Trials Unit, University of Birmingham, Birmingham, UK., Yafai E; CRUK Clinical Trials Unit, University of Birmingham, Birmingham, UK., Boucher R; CRUK Clinical Trials Unit, University of Birmingham, Birmingham, UK., Homer V; CRUK Clinical Trials Unit, University of Birmingham, Birmingham, UK., Toth A; Clatterbridge Cancer Hospital, Liverpool, UK., Chan YLT; Worcestershire Acute Hospitals, Worcester, UK., Randall K; South Warwickshire University NHS Foundation Trust, Warwick, UK., Rider T; Brighton and Sussex University Hospitals NHS Trust, Brighton, UK., O'Nions J; University College London Hospital, London, UK., Drew V; Bradford Teaching Hospital, Bradford, UK., Pillai A; Countess of Chester Hospital, Chester, UK., Dungarwalla M; Milton Keynes University Hospital, Milton Keynes, UK., Murray D; University Hospitals Coventry, Coventry, UK., Khan A; St James Hospital, Leeds, UK., Wandroo F; Sandwell and West Birmingham Hospitals NHS Trust, West Bromwich, UK., Moore S; Royal United Hospital Bath NHS Foundation Trust, Bath, UK., Krishnamurthy P; King's College Hospital, London, UK., Huang YJ; Wirral University Teaching Hospital, Wirral, UK., Knapper S; Cardiff University School of Medicine, Cardiff, UK., Byrne J; Nottingham University Hospitals Trust, Nottingham, UK., Zhao R; Torbay Hospital, Torquay, UK., Craddock C; Centre for Clinical Haematology, Queen Elizabeth Hospital, Birmingham, UK.; CRUK Clinical Trials Unit, University of Birmingham, Birmingham, UK., Parry H; Centre for Clinical Haematology, Queen Elizabeth Hospital, Birmingham, UK.; University of Birmingham, Birmingham, UK., Moss P; Centre for Clinical Haematology, Queen Elizabeth Hospital, Birmingham, UK.; University of Birmingham, Birmingham, UK., Stanworth SJ; Oxford University Hospitals, Oxford, UK.; University of Oxford, Oxford, UK.; NHS Blood and Transplant, Oxford, UK., Lowe DM; University College London, London, UK.; Royal Free London NHS Foundation Trust, London, UK.
Jazyk: angličtina
Zdroj: British journal of haematology [Br J Haematol] 2023 Aug; Vol. 202 (3), pp. 498-503. Date of Electronic Publication: 2023 Jun 12.
DOI: 10.1111/bjh.18894
Abstrakt: Limited data exist on COVID-19 vaccination efficacy in patients with acute myeloid leukemia and myelodysplasia with excess blasts (AML/MDS-EB2). We report results from a prospective study, PACE (Patients with AML and COVID-19 Epidemiology). 93 patients provided samples post-vaccine 2 or 3 (PV2, PV3). Antibodies against SARS-COV-2 spike antigen were detectable in all samples. Neutralization of the omicron variant was poorer than ancestral variants but improved PV3. In contrast, adequate T-cell reactivity to SARS-COV-2 spike protein was seen in only 16/47 (34%) patients PV2 and 23/52 (44%) PV3. Using regression models, disease response (not in CR/Cri), and increasing age predicted poor T cell response.
(© 2023 British Society for Haematology and John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: